Cell and gene therapies (CGT) represent the cutting edge of biotherapeutics, using DNA and life itself as therapeutic agents. CGT process development requires the coordination of many parts, including cells, DNA constructs, and gene delivery vectors. As a key starting material, CGT development requires a constant flow of high-accuracy, long, and complex custom DNA. Elegen is addressing this synthesis bottleneck with its cell-free DNA synthesis process.